STA
MRVI icon

Summit Trail Advisors’s Maravai LifeSciences MRVI Stock Holding History

Summit Trail Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$139K Sell
22,274
-51,657
-70% -$223K ﹤0.01% 1436
2026
Q1 		$209K Sell
73,931
-6,518
-8% -$22.1K ﹤0.01% 1369
2025
Q4 		$261K Sell
80,449
-4,926
-6% -$16.6K ﹤0.01% 1229
2025
Q3 		$245K Buy
85,375
+737
+0.9% +$1.88K ﹤0.01% 1247
2025
Q2 		$204K Buy
+84,638
New +$178K ﹤0.01% 1058

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Summit Trail Advisors's MRVI Position: Q2 2026 in Review

Summit Trail Advisors reduced its Maravai LifeSciences (MRVI) stake by 70% in Q2 2026, selling an estimated $223K and leaving 22,274 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

Summit Trail Advisors first reported a position in MRVI in Q2 2025 and has held it in 5 quarters since. The position peaked at $261K in Q4 2025. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Summit Trail Advisors held 22,274 shares of Maravai LifeSciences worth $139K as of Q2 2026.
  • Summit Trail Advisors sold 51,657 Maravai LifeSciences shares in Q2 2026, an estimated $223K.
  • Maravai LifeSciences made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1436 holding.
  • Summit Trail Advisors first reported a position in Maravai LifeSciences in Q2 2025 and has held it in 5 quarters since.
  • Summit Trail Advisors's Maravai LifeSciences position peaked at $261K in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.